All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Itacitinib and corticosteroids for chronic GvHD

Featured
Jan 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic GvHD.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Annie Im, University of Pittsburgh, Pittsburgh, US. We asked about itacitinib and corticosteroids for chronic graft-versus-host disease.

Itacitinib and corticosteroids for chronic GvHD

Im opens by discussing steroid treatment, which remains the standard of care, and the need for improved therapied based on disease outcomes. Im goes on to outline itacitinib, a JAK1 inhibitor, as a potential new treatment which could be used either alone or in combination with steroids. Im then discusses results from the GRAVITAS-309 trial, including the overall response and adverse events. Finally, Im summarizes the study conclusions on the future of combination treatments involving itacitinib and corticosteroids.